Apr 16, 2020
Aging Populations Will Increase Demand in the $35,802 Million Antithrombotic Drugs Market, Reports TBRC
Aug 05, 2019
New findings provide definitive management guidelines for patients on direct oral anticoagulants with atrial fibrillation undergoing elective procedures or surgeries
Sep 08, 2018
Aniara Diagnostica Launches http://www.DOACtesting.com Providing Specific Product Information For Direct Oral Anticoagulant Testing
Jun 19, 2018
Medisafe Announces Partnership with Boehringer Ingelheim to Support U.S. Pradaxa Patients
Apr 17, 2018
FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa
Mar 09, 2018
Boehringer Ingelheim to Present New Research on Pradaxa and Specific Reversal Agent Praxbind at American College of Cardiology Scientific Session
Feb 16, 2018
Global Stroke Prevention in Atrial Fibrillation Market 2017-2024: Survey of 213 Cardiologists in the US, Japan, and Five Major EU markets Sheds Light on Prescribing Trends in SPAF.
Jan 25, 2018
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
Nov 13, 2017
New RE-VERSE AD(TM) Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery
Nov 13, 2017
New Study Consistent with Trial Results for Dabigatran and Warfarin in Atrial Fibrillation
Nov 10, 2017
Boehringer Ingelheim Presents New Data for Pradaxa® and its Specific Reversal Agent Idarucizumab (Praxbind®) at AHA Scientific Sessions 2017
Aug 27, 2017
RE-DUAL PCI(TM) Results Offer Favorable New Safety Data on Pradaxa®